FDA Approves Ibrance for Advanced Breast Cancer in Postmenopausal Women

FDA Approves Ibrance for Advanced Breast Cancer in Postmenopausal Women
pfizerPfizer, Inc. has been granted accelerated approval from the U.S. Food and Drug Administration for its drug Ibrance (palbociclib) for the treatment of advanced metastatic breast cancer. Ibrance is meant to treat postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer that have not been treated with endocrine therapy. This type of malignancy is caused by cancerous cells in the breast tissue that tend to spread to the surrounding tissue. Ibrance has the capacity to block cyclin-dependent kinases (CDKs) 4 and 6, two molecules responsible for cancer cell proliferation. “The addition of palbociclib to letrozole provides a novel treatment option to women diagnosed with metastatic breast cancer,” said the director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, Richard Pazdur, M.D., in a pr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.